Manchester University Specialty Certificate Examination in Endocrinology and Diabetes Training Course: 24-25 Mar 2017

Dates: 24th  and 25th  March 2017

Venue: Seminar Room A, 5th Floor, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, M13 9WL

Organisers:

Dr Handrean Soran, Consultant Physician & Endocrinologist, Central Manchester University Hospitals Foundation Trust

Dr Naveed Younis, Consultant Physician & Endocrinologist, University Hospital South Manchester Foundation Trust

Co-Organiser: Dr. Moayed Alhelfi (ST7 Diabetes &Endo/NMGH)

This is a two day intensive Endocrine and Diabetes SCE exam course delivered by expert consultants specialised in the field they cover. 14 sessions aiming at covering the curriculum. More than 400 new questions will be discussed. Mock exam will be on day 2 of the course.

Who should attend?

1-    SpRs in Diabetes and Endocrinology,

2-    CMTs who plan a career in this speciality,

3-    Chemical pathology and metabolic medicine trainees,

4-    Any other trainee or HCP who is planning to take the SCE exam or to improve his/her knowledge in diabetes and endocrinology.

5-    Primary care physicians/trainees and overseas doctors are welcome.

 

To reserve your place:

1-   Fill in the registration form then email it to diabendosce2017@gmail.com

2-    Payment £75.00: by cheque (for details see the registration form). The registration fee covers catering but does not cover accommodation or travel. Delegates should arrange their own accommodation and travel.

For any enquires, please contact Dr.Mo Alhelfi (diabendosce2017@gmail.com)

Semaglutide and CV Outcomes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834-1844

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.

http://www.nejm.org/doi/full/10.1056/NEJMoa1607141